^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Testicular Cancer

    Related cancers:
    2d
    RPLND: Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. (clinicaltrials.gov)
    P3, N=142, Recruiting, Indiana University | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P3
    Enrollment open • Phase classification
    3d
    Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    cisplatin • albumin-bound paclitaxel • cyclophosphamide • ifosfamide
    5d
    A Prospective Observational Study Evaluating a Predictive System that Combines Radiomics and Serum MicroRNA for Forecasting Postoperative Pathology in Retroperitoneal Retroperitoneal Lymph Node Dissection for Testicular Cancer (ChiCTR2400090744)
    P=N/A, N=0, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    7d
    A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors (clinicaltrials.gov)
    P1, N=197, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1 trial • Metastases
    10d
    Pancancer analysis of the interactions between CTNNB1 and infiltrating immune cell populations. (PubMed, Medicine (Baltimore))
    Additionally, pathway enrichment suggested that NUMB is involved in the Wnt pathway. This study highlights the predictive role of CTNNB1 across cancers, suggesting that CTNNB1 might serve as a potential biomarker for the diagnosis and prognosis evaluation of various malignant tumors.
    Journal • Pan tumor • Immune cell
    |
    CD8 (cluster of differentiation 8) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RHOA (Ras homolog family member A)
    |
    CTNNB1 mutation • CTNNB1 expression
    11d
    Genomic Structural Variation in Cancer Susceptibility (clinicaltrials.gov)
    P=N/A, N=1275, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    14d
    Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B. (PubMed, Res Sq)
    In this report, we demonstrate for the first time that targeting polycomb demethylases KDM6A and KDM6B with epidrug GSK-J4 can treat both cisplatin-sensitive and -resistant TGCTs. Further, several chromatin modifier genes, including BRD4 , lysine demethylases, chromodomain helicase DNA binding proteins, and lysine methyltransferases, were repressed with cisplatin only in KDM6A/KDM6B-targeted cells, implying that KDM6A/KDM6B inhibition sets the stage for extensive chromatin remodeling of TGCT cells upon cisplatin treatment. Our findings demonstrate that targeting polycomb demethylases is a new potent pharmacologic strategy for treating cisplatin resistant TGCTs that warrants clinical development.
    Journal
    |
    KDM6A (Lysine Demethylase 6A) • BRD4 (Bromodomain Containing 4) • KDM6B (Lysine Demethylase 6B)
    |
    cisplatin • GSKJ4
    14d
    Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B. (PubMed, Cell Commun Signal)
    While GSK-J4 had minimal effects alone on TGCT tumor growth in vivo, it dramatically sensitized cisplatin-sensitive and -resistant TGCTs to cisplatin...Further, several chromatin modifier genes, including BRD4, lysine demethylases, chromodomain helicase DNA binding proteins, and lysine methyltransferases, were repressed with cisplatin only in KDM6A/KDM6B-targeted cells, implying that KDM6A/KDM6B inhibition sets the stage for extensive chromatin remodeling of TGCT cells upon cisplatin treatment. Our findings demonstrate that targeting polycomb demethylases is a new potent pharmacologic strategy for treating cisplatin resistant TGCTs that warrants clinical development.
    Journal
    |
    KDM6A (Lysine Demethylase 6A) • BRD4 (Bromodomain Containing 4) • KDM6B (Lysine Demethylase 6B)
    |
    cisplatin • GSK2816126 • GSKJ4
    15d
    Chemokine Profile Is Different in Normal Testis Compared to Seminoma - Especially in Tumor Infiltrating Lymphocytes. (PubMed, Anticancer Res)
    The involvement of TILs in seminoma biology warrants further investigation, especially their role in the tumor micro-environment and pathogenesis. Chemokine and Ki-67 expression in TILs could serve as potential markers for assessing seminoma prognosis.
    Journal • Tumor-infiltrating lymphocyte
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CXCL13 expression
    16d
    Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Eastern Cooperative Oncology Group | Trial completion date: Nov 2024 --> May 2027 | Trial primary completion date: Nov 2024 --> May 2027
    Trial completion date • Trial primary completion date
    16d
    A Comprehensive Pan-Cancer Analysis of the Mitochondrial Uncoupling Protein UCP2, with a Focus on Sex and Gender-Related Aspects. (PubMed, Cell Physiol Biochem)
    Our findings highlight the interplay between UCP2, immune and hormonal pathways, and drug response and reveal potential opportunities for new therapeutic combinations, especially in gender-related cancers.
    Journal • Tumor mutational burden • BRCA Biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    18d
    Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases. (PubMed, Hum Pathol)
    Despite surgery and chemotherapy, two patients died of disease 17 months after ETT diagnosis, and three patients were alive with metastatic disease at a mean of 20 months (range, 15-28 months). Our results demonstrate that ETT may be an aggressive disease associated with distinct pathologic features and poor clinical outcome.
    Journal
    |
    SALL4 (Spalt Like Transcription Factor 4) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
    19d
    Busulfan Chemotherapy Downregulates TAF7/TNF-α Signaling in Male Germ Cell Dysfunction. (PubMed, Biomedicines)
    Thus, our data indicate a possible function of TAF7 in the regulation of SSCs and spermatogenesis following downregulation by Busulfan. These findings may account for the therapeutic effects of Busulfan and underlie its potential impact on cancer chemotherapy prognosis.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    busulfan
    21d
    Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. (PubMed, JCO Precis Oncol)
    To our knowledge, this is the first series of NC profiled broadly at the DNA and RNA level. We observed fewer intratumoral immune cells by RNA sequencing, which may be associated with anecdotal data of lack of immunotherapy benefit in NC. High MYC pathway activity in NC supports ongoing trials targeting MYC suppression. The incidence of NC among patients younger than 50 years with LUSC/HNSCC supports testing for NC in these patients. The prognosis of NCs remains dismal, and future studies should focus on improving the response to immunotherapy and targeting MYC.
    Journal • IO biomarker
    |
    NUTM1 (NUT Midline Carcinoma Family Member 1)
    22d
    Male Infertility associated with a Novel PRKAR1A Mutation in Carney Complex. (PubMed, Clin Med Insights Endocrinol Diabetes)
    Accordingly, in male patients with CNC, detection of a PRKAR1A gene mutation may serve as a predictive marker for infertility. This case report illustrates the importance of early consideration and management of infertility in male patients diagnosed with CNC.
    Journal
    |
    PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha)
    22d
    New tumor markers for testicular cancer - in the here and now and in the future (PubMed, Aktuelle Urol)
    Research is also currently being conducted on circulating tumor cells (CTCs) and cell-free DNA (cfNA) in various areas of application. With regard to germ cell tumors of the testis, however, these analyses are still in their infancy, but it is hoped that this will provide a further sufficient opportunity to use serum tumor markers.
    Journal
    |
    AFP (Alpha-fetoprotein)
    29d
    Estrogen receptor activates SRC and ERK1/2 and promotes tumorigenesis in human testicular embryonic carcinoma cells NT2/D1. (PubMed, Exp Cell Res)
    Finally, the proliferation, migration, and invasion of NT2/D1 cells simulated by E2 or ESR2 were also blocked by PP2 and U0126. This study provides novel insights into molecular mechanisms of ER in NT2/D1 cells by demonstrating that ER activates rapid responses molecules, including SRC and ERK1/2, which enhance the tumorigenic potential of testicular cancer cells.
    Journal
    |
    ER (Estrogen receptor)
    29d
    Scrotal cellular angiofibroma: A case report and review of the literature. (PubMed, Urol Case Rep)
    Our series is one of the only published to date demonstrating desmin-positive paratesticular CAF. Diagnosis of CAF remains difficult due to the sparsity of paratesticular CAF, its similar characteristics to spindle cell lipoma (SCL), and variability in immunohistochemical reporting.
    Review • Journal
    |
    ER (Estrogen receptor) • CD34 (CD34 molecule)
    1m
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies. (PubMed, Clin Cancer Res)
    Ongoing data collection highlights the role of lung surveillance in the detection of early PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before age 8 years, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.
    Journal
    |
    DICER1 (Dicer 1 Ribonuclease III)
    1m
    Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors? (PubMed, Gynecol Oncol Rep)
    PD-L1 expression does not predict response, but microsatellite instability status may serve as a potential biomarker. MSI testing should be performed on a recurrent tumour sample as MSI status may evolve during treatment.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression
    1m
    Anticancer potential of isoalantolactone in testicular cancer: an analysis of cytotoxicity, apoptosis, and signaling pathways. (PubMed, Aging (Albany NY))
    Moreover, IATL induced ferroptosis by modulating expression levels of GPX4, xCT, NRF2, and HO-1. Our findings shed light on IATL's multifaceted anticancer mechanisms, emphasizing its potential as a therapeutic candidate for testicular cancer.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • GPX4 (Glutathione Peroxidase 4) • ANXA5 (Annexin A5)
    |
    HIF1A expression
    1m
    EARN: Enhanced Assistance During Radiotherapy for Unmet Essential Needs (clinicaltrials.gov)
    P=N/A, N=33, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    SWENOTECA-ABC: Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer (clinicaltrials.gov)
    P3, N=348, Active, not recruiting, St. Olavs Hospital | Trial completion date: Dec 2035 --> May 2032 | Trial primary completion date: Dec 2035 --> May 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    cisplatin • carboplatin • etoposide IV • bleomycin
    1m
    Sustained response to anti-PD-1 therapy in combination with nab-paclitaxel in metastatic testicular germ cell tumor harboring the KRAS-G12V mutation: a case report. (PubMed, Urol Int)
    To the best of our knowledge, this is the first successful case of KRAS-mutation patient with TGCT who achieved partially and sustained disease remission by combining immune checkpoint inhibitors with chemotherapy. This case provides an excellent example for personalized treatment of metastatic TGCTs.
    Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12V • KRAS G12
    |
    cisplatin • albumin-bound paclitaxel
    1m
    VEGF-dependent testicular vascularisation involves MEK1/2 signalling and the essential angiogenesis factors, SOX7 and SOX17. (PubMed, BMC Biol)
    Together, our data highlight an essential role for VEGF-dependent MEK1/2 signalling in promoting vasculature and indicate that FGF signalling through MEK1/2 regulates Sertoli cell organisation in the developing mouse testis.
    Journal
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • POU5F1 (POU Class 5 Homeobox 1) • SOX17 (SRY-Box Transcription Factor 17) • SOX9 (SRY-Box Transcription Factor 9) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CDH5 (Cadherin 5) • GJA4 (Gap Junction Protein Alpha 4)
    1m
    SWOG-S1823: A Study of miRNA 371 in Patients With Germ Cell Tumors (clinicaltrials.gov)
    P=N/A, N=956, Active, not recruiting, SWOG Cancer Research Network | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AFP (Alpha-fetoprotein)
    1m
    SEARCH-1: Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses. (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New trial
    1m
    TESTPET: Role of Axumin PET Scan in Germ Cell Tumor (clinicaltrials.gov)
    P=N/A, N=10, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    2ms
    Synchronous Seminoma of Testis and Renal Cell Carcinoma: A Rare Case Report. (PubMed, Medicina (Kaunas))
    Chemotherapy with a Bleomycin, Etoposide, and Cisplatin (BEP) regimen was carried out...Treatment with targeted therapy with Sunitinib was started because the risk was favourable according to the Heng criteria... According to the authors, the occurrence of synchronous primary tumours is linked to one's genetic predisposition. DNA sequencing of tumour tissue could provide more information on the corresponding aetiopathogenesis.
    Journal
    |
    STK11 (Serine/threonine kinase 11) • BAP1 (BRCA1 Associated Protein 1) • CHEK2 (Checkpoint kinase 2) • MUTYH (MutY homolog)
    |
    cisplatin • sunitinib • etoposide IV • bleomycin
    2ms
    An observation study to measure cognitive function in patients with testicular cancer who go on to have chemotherapy after surgery compared to those who don not have chemotherapy. (ACTRN12609000545268)
    P=N/A, N=154, Completed, The University of Sydney | Active, not recruiting --> Completed
    Trial completion • Surgery
    2ms
    Expression of Heat Shock Protein 90 in Testicular Cancer: A Retrospective Cohort Study. (PubMed, Rev Recent Clin Trials)
    HSP90b is highly expressed in the majority of the types of testicular tumors, both in tumor and normal parenchyma specimens, while HSP90a staining is negative in resected specimens. Further well-designed studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.
    Retrospective data • Journal
    |
    HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
    2ms
    Mucinous Carcinoma in a Male: First Documented Case in Nicaragua. (PubMed, Cureus)
    This case also underscores the disparity in breast cancer outcomes between low gross domestic product (GDP) and high-GDP countries, emphasizing the need for improved access to diagnostic and therapeutic resources. Enhanced clinical awareness and early detection are crucial for improving outcomes in patients with rare histological subtypes, particularly in underserved regions.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    2ms
    A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects. (PubMed, Pediatr Allergy Immunol)
    Differential diagnosis with combined immunodeficiency and diseases of immune dysregulation make molecular genetic analysis crucial for diagnosing mTOR pathway defects. It is easy to differentiate APDS and homozygous PIK3R1 defects with specific laboratory features. Additionally, mTOR pathway functional analysis is a definitive diagnostic and pathogenicity assessment tool for novel APDS mutations.
    Journal
    |
    PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • CD4 (CD4 Molecule)
    |
    PIK3R1 mutation • PIK3CD mutation
    2ms
    PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA. (PubMed, Elife)
    While PITAR silencing inhibited the growth of WT p53 containing GSCs in vitro and reduced glioma tumor growth in vivo, its overexpression enhanced the tumor growth in a TRIM28-dependent manner and promoted resistance to Temozolomide. Thus, we establish an alternate way of p53 inactivation by PITAR, which maintains low p53 levels in normal cells and attenuates the DNA damage response by p53. Finally, we propose PITAR as a potential GBM therapeutic target.
    Journal
    |
    TRIM28 (Tripartite Motif Containing 28)
    |
    TP53 wild-type
    |
    temozolomide
    2ms
    Establishment of tumor microenvironment following bisphenol A exposure in the testis. (PubMed, Ecotoxicol Environ Saf)
    Number of testicular blood vessels were approximately 2-times increased by upregulation of matrix metallopeptidase 2 in TAMs and upregulation of AR expression in the nucleus of Leydig cells. Moreover, we found that the tumor-supportive environment can also be generated even though NOAEL BPA concentration due to the individual's variability in cancer susceptibility.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL10 (Interleukin 10) • TLR2 (Toll Like Receptor 2)
    |
    AR expression
    2ms
    Aging-related biomarkers in testicular cancer survivors after different oncologic treatments. (PubMed, Cancer Med)
    Among TCS, only patients exposed to cytotoxic agents developed an immunosenescent phenotype. This finding supports the attribution of this alteration to the cytotoxic treatment.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CRP (C-reactive protein)
    2ms
    Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy. (PubMed, ACS Pharmacol Transl Sci)
    The mode of action for Platin-L is inhibition of fatty acid oxidation (FAO) of prostate cancer cells. We demonstrated that FAO inhibition by Platin-L in PCa cells contribute to AR regulation resulting in altered tumorigenicity of androgen sensitive prostate cancer.
    Journal
    |
    AR (Androgen receptor)
    2ms
    Exploring the environmental contamination toxicity and potential carcinogenic pathways of perfluorinated and polyfluoroalkyl substances (PFAS): An integrated network toxicology and molecular docking strategy. (PubMed, Heliyon)
    It revealed their toxicity mechanisms in inducing thyroid, renal, and testicular cancers, and provided a solid theoretical foundation for designing new environmental control strategies and drug screening initiatives. Additionally, the integrated application of network toxicology and molecular docking technology can enhance our understanding of the toxicity and mechanisms of unknown environmental pollutants, which is beneficial for protecting the environment and human health.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    2ms
    Thyroid Carcinoma With NSD3::NUTM1 Fusion and Secondary TERT Promoter Mutation: A Case Report and Literature Review. (PubMed, Int J Surg Pathol)
    Molecular analysis revealed a concurrent TERT promoter mutation (C228T) together with the NSD3::NUTM1 fusion, a combination not previously documented in NUT carcinoma. The tumor highlights the need to include NUT carcinoma in the differential diagnosis of thyroid cancer, especially when it presents with unconventional histopathological features, even in the absence of signs of squamous differentiation.
    Review • Journal
    |
    TERT (Telomerase Reverse Transcriptase) • NKX2-1 (NK2 Homeobox 1) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • NUTM1 (NUT Midline Carcinoma Family Member 1) • PAX8 (Paired box 8)
    |
    TERT mutation • TERT promoter mutation
    2ms
    RPLND: Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. (clinicaltrials.gov)
    P=N/A, N=142, Not yet recruiting, Indiana University
    New trial
    2ms
    A fibroblastic reticular cell tumour as unexpected diagnosis (ECP 2024)
    Fibroblastic reticular cell tumour (FRCT) is a rare tumour with 21 cases reported in the literature. FRCTs are characterized by cells arranged in a whorls, fascicles or sheets accompanied by lymphoplasmacytic infiltrate. FRCT shows overlapping morphological features with follicular dendritic cell sarcoma (FDCS) and interdigitating dendritic cell sarcoma (IDCS).
    IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • CD38 (CD38 Molecule) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD123 (Interleukin 3 Receptor Subunit Alpha) • EWSR1 (EWS RNA Binding Protein 1) • PAX5 (Paired Box 5) • ALPP (Alkaline Phosphatase, Placental) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • VIM (Vimentin) • CD68 (CD68 Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • SALL4 (Spalt Like Transcription Factor 4) • TP63 (Tumor protein 63) • PAX8 (Paired box 8) • SPN (Sialophorin) • CR1 (Complement C3b/C4b Receptor 1)
    |
    CDKN2A deletion • VIM expression
    |
    Archer® FusionPlex® Sarcoma kit
    2ms
    Preliminary Evidence of the Possible Roles of the Ferritinophagy-Iron Uptake Axis in Canine Testicular Cancer. (PubMed, Animals (Basel))
    Sertoli cell tumors (SCTs) showed only NCOA4 expression. These preliminary findings highlight potential molecular targets for developing new anti-neoplastic treatments in canine testicular tumors.
    Journal
    |
    NCOA4 (Nuclear Receptor Coactivator 4) • TFRC • PCNA (Proliferating cell nuclear antigen) • FTH1 (Ferritin Heavy Chain 1)
    |
    TFRC expression • PCNA expression